Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

A new once-day pill made by AstraZeneca has the ability to delay breast cancer progression in those in the advanced stages ...

A recently published study confirms what caffeine enthusiasts have suspected all along: the naturally occurring stimulant is ...

Protein kinase inhibitors have applications as anticancer therapeutic agents and biological tools in cell signaling. Based on a phosphoryl transfer mechanism involving a dissociative transition ...

Researchers at the Francis Crick Institute have shown that the 'pacemaker' controlling yeast cell division lies inside the ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

The insulin receptor (IR) is a prototypical receptor tyrosine kinase that orchestrates critical cellular processes, including metabolism, cell growth and differentiation. Activation of the IR ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Gilead Sciences Inc. and Kymera Therapeutics Inc. have entered into an exclusive option and license agreement.

Please enter your username and password below, if you are not yet a member of BioTechniques remember you can register for ...

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.